Market Overview

NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported that three abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism will be presented at ENDO 2012, the annual meeting of The Endocrine Society in Houston, TX, June 23-26, 2012.

Posted-In: News FDA Events

 

Most Popular

Related Articles (NPSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free